Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients
The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.
Hodgkin Lymphoma
DRUG: Doxorubicine|DRUG: DTIC|DRUG: Lenalidomide|DRUG: Vinblastine
Dose limiting toxicities (DLT)
Overall response rate (ORR)|Progression free survival (PFS), 2 years
The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.